Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats

Molecular Pharmaceutics

Volumn 5, Issue 2, 2008, Pages 316-327

  Jain, Tapan K ^a   Reddy, Maram K ^a   Morales, Marco A ^b   Leslie Pelecky, Diandra L ^b   Labhasetwar, Vinod ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Drug delivery; Imaging; MRI; Nanotoxicity; Oxidative stress

Indexed keywords

DRUG CARRIER; IRON OXIDE; NANOPARTICLE; OLEIC ACID; POLOXAMER; POLYGLACTIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCOMPATIBILITY; BRAIN; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; HEART; HISTOLOGY; IMAGING SYSTEM; IRON BINDING CAPACITY; IRON BLOOD LEVEL; KIDNEY; KIDNEY PARENCHYMA; LIVER; LIVER FUNCTION; LUNG; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPLEEN;

ALANINE TRANSAMINASE; ANIMALS; DRUG CARRIERS; FERRIC COMPOUNDS; IRON; LIVER; MAGNETIC RESONANCE IMAGING; MAGNETICS; MALE; MATERIALS TESTING; METABOLIC CLEARANCE RATE; NANOPARTICLES; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 42549152143     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp7001285     Document Type: Article

References (50)

1. Alexiou, C.; Arnold, W.; Klein, R. J.; Parak, F. G.; Hulin, P.; Bergemann, C.; Erhardt, W.; Wagenpfeil, S.; Lubbe, A. S. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000, 60, 6641-6648.
2. Alexiou, C.; Jurgons, R.; Schmid, R. J.; Bergemann, C.; Henke, J.; Erhardt, W.; Huenges, E.; Parak, F. Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J. Drug Target. 2003, 11, 139-149.
3. Clement, J. H.; Schwalbe, M.; Buske, N.; Wagner, K.; Schnabelrauch, M.; Gornert, P.; Kliche, K. O.; Pachmann, K.; Weitschies, W.; Hoffken, K. Differential interaction of magnetic nanoparticles with tumor cells and peripheral blood cells. J. Cancer Res. Clin. Oncol. 2006, 132, 287-292.
4. Artemov, D. Molecular magnetic resonance imaging with targeted contrast agents. J. Cell. Biochem. 2003, 90, 518-524.
5. Jung, C. W.; Jacobs, P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn. Reson. Imaging 1995, 13, 661-674.
6. Ito, A.; Tanaka, K.; Kondo, K.; Shinkai, M.; Honda, H.; Matsumoto, K.; Saida, T.; Kobayashi, T. Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Sci. 2003, 94, 308-313.
7. Jain, T. K.; Morales, M. A.; Sahoo, S. K.; Leslie-Pelecky, D. L.; Labhasetwar, V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol. Pharm. 2005, 2, 194-205.
8. Koning, G. A.; Krijger, G. C. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med. Chem. 2007, 7, 425-440.
9. Broxterman, H. J.; Lankelma, J.; Hoekman, K. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist. Updat. 2003, 6, 111-127.
10. Bezwoda, W. R. High-dose chemotherapy with hematopoietic rescue in breast cancer: from theory to practice. Cancer Chemother. Pharmacol. 1997, 40, S79-S87.
11. Frank, J. A.; Miller, B. R.; Arbab, A. S.; Zywicke, H. A.; Jordan, E. K.; Lewis, B. K.; Bryant, L. H. Jr.; Bulte, J. W. M. Clinically Applicable Labeling of Mammalian and Stem Cells by Combining Superparamagnetic Iron Oxides and Transfection Agents. Radiology 2003, 228, 480-487.
12. Gupta, A. K.; Naregalkar, R. R.; Vaidya, V. D.; Gupta, M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomed. 2007, 2, 23-39.
13. Weissleder, R.; Moore, A.; Mahmood, U.; Bhorade, R.; Benveniste, H.; Chiocca, E. A.; Basilion, J. P. In vivo magnetic resonance imaging of transgene expression. Nat. Med. 2000, 6, 351-355.
14. Chouly, C.; Pouliquen, D.; Lucet, I.; Jeune, J. J.; Jallet, P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J. Microencapsul. 1996, 13, 245-255.
15. Owens, D. E.; Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307, 93-102.
16. Gupta, A. K.; Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26, 3995-4021.
17. Weir, M. P.; Gibson, J. F.; Peters, T. J. Haemosiderin and tissue damage. Cell Biochem. Funct. 1984, 2, 186-194.
18. Jeffery, G. H.; Bassett, J.; Mendham, J. Denny, R. C. Vogel's Text Book of Quantitative Chemical Analysis, 5th ed.; John Wiley & Sons, Inc.: New York, 1989; pp 690-692.
19. Davda, J.; Labhasetwar, V. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 2002, 233, 51-59.
20. Stearns, M. B.; Cheng, Y. Determination of para- and ferromagnetic components of magnetization and magnetoresistance of granular Co/Ag films. J. Appl. Phys. 1994, 75, 6894-6899.
21. Noyau, R. H.; Middleton, B. K.; Miles, J. J.; Mackintosh, N. D. Modelling digital recording in thin film media. IEEE Trans. Magn. 1988, 24, 2494-2496.
22. Mihaljevic, B.; Katusin-Razem, B.; Razem, D. The reevaluation of the ferric thiocyanate assay for lipid hydroperoxides with special considerations of the mechanistic aspects of the response. Free Radic. Biol. Med. 1996, 21, 53-63.
23. LaConte, L.; Nitin, N.; Bao, G. Magnetic nanoparticle probes. Mater. Today 2005, 8, 32-38.
24. McCord, J. M. Effects of positive iron status at a cellular level. Nutr. Rev. 1996, 54, 85-88.
25. Bourrinet, P.; Bengele, H. H.; Bonnemain, B.; Dencausse, A.; Idee, J. M.; Jacobs, P. M.; Lewis, J. M. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest. Radiol. 2006, 41, 313-324.
26. Weissleder, R.; Stark, D. D.; Engelstad, B. L.; Bacon, B. R.; Compton, C. C.; White, D. L.; Jacobs, P.; Lewis, J. Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am. J. Roentgenol. 1989, 152, 167-173.
27. Neuberger, T.; Schopf, B.; Hofmann, H.; Hofmann, M.; von Rechenberg, B. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J. Magn. Magn. Mater. 2005, 293, 483-496.
28. Briley-Saebo, K.; Bjornerud, A.; Grant, D.; Ahlstrom, H.; Berg, T.; Kindberg, G. M. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res. 2004, 316, 315-323.
29. Okon, E.; Pouliquen, D.; Okon, P.; Kovaleva, Z. V.; Stepanova, T. P.; Lavit, S. G.; Kudryavtsev, B. N.; Jallet, P. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. Lab. Invest. 1994, 71, 895-903.
30. Tan, J. S.; Butterfield, D. E.; Voycheck, C. L.; Caldwell, K. D.; Li, J. T. Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. Biomaterials 1993, 14, 823-833.
31. Moghimi, S. M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42, 463-478.
32. Corot, C.; Robert, P.; Idee, J.-M.; Port, M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 2006, 58, 1471-1504.
33. Schulze, E.; Ferrucci, J. T. Jr.; Poss, K.; Lapointe, L.; Bogdanova, A.; Weissleder, R. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest. Radiol. 1995, 30, 604-610.
34. Descamps, L.; Dehouck, M. P.; Torpier, G.; Cecchelli, R. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 1996, 270, H1149-H1158.
35. Gaasch, J. A.; Lockman, P. R.; Geldenhuys, W. J.; Allen, D. D.; Van der Schyf, C. J. Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells. Neurochem. Res. 2007, 32, 1196-1208.
36. Kim, J. S.; Yoon, T.-J.; Yu, K. N.; Kim, B. G.; Park, S. J.; Kim, H. W.; Lee, K. H.; Park, S. B.; Lee, J.-K.; Cho, M. H. Toxicity and Tissue Distribution of Magnetic Nanoparticles in Mice. Toxicol. Sci. 2006, 89, 338-347.
37. Qian, Z. M.; Chang, Y. Z.; Leung, G.; Du, J. R.; Zhu, L.; Wang, Q.; Niu, L.; Xu, Y. J.; Yang, L.; Ho, K. P.; Ke, Y. Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart. Biochim. Biophys. Acta 2007, 1772, 527-532.
38. Cook, C. I.; Yu, B. P. Iron accumulation in aging: modulation by dietary restriction. Mech. Ageing Dev. 1998, 102, 1-13.
39. Tiefenauer, L. X.; Tschirky, A.; Kuhne, G.; Andres, R. Y. In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI. Magn. Reson. Imaging 1996, 14, 391-402.
40. Thompson, J. S.; Brown, S. A.; Khurdayan, V.; Zeynalzadedan, A.; Sullivan, P. G.; Scheff, S. W. Early effects of tribromoethanol, ketamine/xylazine, pentobarbitol, and isoflurane anesthesia on hepatic and lymphoid tissue in ICR mice. Comp. Med. 2002, 52, 63-67.
41. Jiang, X.; Dai, H.; Leong, K. W.; Goh, S. H.; Mao, H. Q.; Yang, Y. Y. Chitosan-g-PEG/DNA complexes deliver gene to the rat liver via intrabiliary and intraportal infusions. J. Gene Med. 2006, 8, 477-487.
42. Dufour, D. R. Liver Disease. In Tietz textbook of clinical chemistry and molecular diagnostics, 4th ed.; Burtis, C. A., Ashwood, E. R., Bruns, D. E., Eds.; Elsevier Saunders: St. Louis, MO, 2006; 1777-1848.
43. Olfert, E. D., Cross, B. M., McWilliam, A. A., Eds. Guide to the Care and Use of Experimental Animals, 2nd ed.; Canadian Council on Animal Care: Ottawa, 1993.
44. Puntarulo, S. Iron, oxidative stress and human health. Mol. Aspects Med. 2005, 26, 299-312.
45. Mehta, S. H.; Webb, R. C.; Ergul, A.; Tawak, A.; Dorrance, A. M. Neuroprotection by tempol in a model of iron-induced oxidative stress in acute ischemic stroke. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286, R283-R288.
46. Minotti, G. Sources and role of iron in lipid peroxidation. Chem. Res. Toxicol. 1993, 6, 134-146.
47. Stroh, A.; Zimmer, C.; Gutzeit, C.; Jakstadt, M.; Marschinke, F.; Jung, T.; Pilgrimm, H.; Grune, T. Iron oxide particles for molecular magnetic resonance imaging cause transient oxidative stress in rat macrophages. Free Radic. Biol. Med. 2004, 36, 976-984.
48. Fernandez-Urrusuno, R.; Fattal, E.; Feger, J.; Couvreur, P.; Therond, P. Evaluation of hepatic antioxidant systems after intravenous administration of polymeric nanoparticles. Biomaterials 1997, 18, 511-517.
49. Anthony, S.; Tavill, B. R. B. Hemochromatosis: How much iron is too much. Hepatology 1986, 6, 142-145.
50. Bassett, M. L.; Halliday, J. W.; Powell, L. W. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986, 6, 24-29.